Medexus Pharmaceuticals (TSX:MDP) Stock Price & Quote Analysis

MDP fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	2/6
Financial Health	0/6
Dividends	0/6

MDP Stock Overview

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States.

Rewards

Trading at 69.3% below our estimate of its fair value

Earnings are forecast to grow 68.76% per year

Became profitable this year

Risk Analysis

Debt is not well covered by operating cash flow

Large one-off items impacting financial results

Shareholders have been diluted in the past year

Does not have a meaningful market cap (CA$58M)

Medexus Pharmaceuticals Inc. Competitors

Vext Science

CNSX:VEXT

CA$57.4m

C21 Investments

CNSX:CXXI

CA$46.2m

Cipher Pharmaceuticals

TSX:CPH

CA$61.0m

BioSyent

TSXV:RX

CA$99.3m

Price History & Performance

Summary of all time highs, changes and price drops for Medexus Pharmaceuticals
Historical stock prices
Current Share Price	CA$2.90
52 Week High	CA$4.58
52 Week Low	CA$1.59
Beta	1.12
1 Month Change	58.47%
3 Month Change	10.69%
1 Year Change	11.11%
3 Year Change	-27.32%
5 Year Change	-35.56%
Change since IPO	-61.33%

Shareholder Returns

	MDP	CA Pharmaceuticals	CA Market
7D	-3.3%	5.6%	3.2%
1Y	11.1%	-61.8%	2.1%

Return vs Industry: MDP exceeded the Canadian Pharmaceuticals industry which returned -61.8% over the past year.

Return vs Market: MDP exceeded the Canadian Market which returned 2.1% over the past year.

Price Volatility

Is MDP's price volatile compared to industry and market?
MDP volatility
MDP Average Weekly Movement	10.4%
Pharmaceuticals Industry Average Movement	13.6%
Market Average Movement	10.6%
10% most volatile stocks in CA Market	18.9%
10% least volatile stocks in CA Market	4.3%

Stable Share Price: MDP is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: MDP's weekly volatility (10%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	100	Ken d'Entremont	https://www.medexus.com

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company’s primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication.

Medexus Pharmaceuticals Inc. Fundamentals Summary

How do Medexus Pharmaceuticals's earnings and revenue compare to its market cap?
MDP fundamental statistics
Market Cap	CA$57.87m
Earnings (TTM)	CA$2.99m
Revenue (TTM)	CA$106.59m

19.4x

P/E Ratio

0.5x

P/S Ratio

Is MDP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MDP income statement (TTM)
Revenue	US$82.48m
Cost of Revenue	US$32.79m
Gross Profit	US$49.69m
Other Expenses	US$47.38m
Earnings	US$2.31m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	0.12
Gross Margin	60.24%
Net Profit Margin	2.80%
Debt/Equity Ratio	323.3%

How did MDP perform over the long term?

See historical performance and comparison

Medexus Pharmaceuticals TSX:MDP Stock Report

Last Price

Market Cap

7D

1Y

Updated

Data